Epigenetic regulation of cystatins in cancer

Frontiers in Bioscience

Volumn 14, Issue 2, 2009, Pages 453-462

  Rivenbark, Ashley G ^a   Coleman, William B ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Cystatins; Cysteine protease inhibitor; DNA methylation; Epigenetic; Review

Indexed keywords

CYSTATIN;

CHEMISTRY; GENETIC EPIGENESIS; GENETICS; HUMAN; METABOLISM; NEOPLASM; REVIEW; STRUCTURE ACTIVITY RELATION;

CYSTATINS; EPIGENESIS, GENETIC; HUMANS; NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 63849236804     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/3254     Document Type: Review

References (92)

1. Herman, J. G. and S. B. Baylin: Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349, 2042-54(2003) (Pubitemid 37448928)
2. Jones, P. A. and D. Takai: The role of DNA methylation in mammalian epigenetics. Science 293, 1068-70(2001) (Pubitemid 32758075)
3. Takai, D. and P. A. Jones: Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc Natl Acad Sci U S A 99, 3740-5(2002) (Pubitemid 34252176)
4. Bird, A. P.: CpG-rich islands and the function of DNA methylation. Nature 321, 209-13(1986) (Pubitemid 16016411)
5. Razin, A. and A. D. Riggs: DNA methylation and gene function. Science 210, 604-10(1980)
6. Razin, A. and M. Szyf: DNA methylation patterns. Formation and function. Biochim Biophys Acta 782, 331-42(1984) (Pubitemid 14038241)
7. Jones, P. A. and S. B. Baylin: The fundamental role of epigenetic events in cancer. Nat Rev Genet 3, 415-28(2002) (Pubitemid 34587077)
8. Jones, P. A. and P. W. Laird: Cancer epigenetics comes of age. Nat Genet 21, 163-7(1999) (Pubitemid 29070360)
9. Hanahan, D. and R. A. Weinberg: The hallmarks of cancer. Cell 100, 57-70(2000) (Pubitemid 30046295)
10. Rivenbark, A. G., W. D. Jones, J. D. Risher and W. B. Coleman: DNA methylation-dependent epigenetic regulation of gene expression in MCF-7 breast cancer cells. Epigenetics 1, 32-44(2006)
11. Rivenbark, A. G., W. D. Jones and W. B. Coleman: DNA methylation- dependent silencing of CST6 in human breast cancer cell lines. Lab Invest 86, 1233-1242(2006) (Pubitemid 44789913)
12. Ai, W. J. Kim, T. Y. Kim, C. R. Fields, N. A. Massoll, K. D. Robertson and K. D. Brown: Epigenetic Silencing of the Tumor Suppressor Cystatin M Occurs during Breast Cancer Progression. Cancer Res 66, 7899-7909(2006) (Pubitemid 44299152)
13. Schagdarsurengin, U., G. P. Pfeifer and R. Dammann: Frequent epigenetic inactivation of cystatin M in breast carcinoma. Oncogene, Epub (2006)
14. Kim, T. Y., S. Zhong, C. R. Fields, J. H. Kim and K. D. Robertson: Epigenomic profiling reveals novel and frequent targets of aberrant DNA methylation-mediated silencing in malignant glioma. Cancer Res 66, 7490-501(2006) (Pubitemid 44289203)
15. Zhong, S., C. R. Fields, N. Su, Y. X. Pan and K. D. Robertson: Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer. Oncogene, Epub (2006)
16. Hayashi, H., A. Tokuda and K. Udaka: Biochemical study of cellular antigen-antibody reaction in tissue culture. I. Activation and release of a protease. J. Exp. Med. 112, 237-247(1960)
17. Keppler, D.: Towards novel anti-cancer strategies based on cystatin function. Cancer Lett 235, 159-76(2006)
18. Dubin, G.: Proteinaceous cysteine protease inhibitors. Cell. Mol. Life Sci. 62, 653-669(2005)
19. Katunuma, N., T. Towatari, E. Kominami, S. Hashida, K. Takio and K. Titani: Rat liver thiol porteinases: cathepsin B, cathepsin H, and catepsin L. Acta Biol. Med. Ger. 40, 1419-1425(1981) (Pubitemid 12022355)
20. Takio, K., T. Towatari, N. Katunuma, D. Teller and K. Titani: Homology of amino acid sequences of rat liver cathepsins B and H with that of papain. Proc. Natl Acad. Sci. USA 80, 3666-3670(1983)
21. Levicar, N., T. Strojnik, J. Kos, R. Dewey, G. Pilkington and T. Lah: Lysosomal enzymes, cathepsins in brain tumour invasion. J. of Neuro-Oncol. 58, 21-32(2002) (Pubitemid 34716197)
22. Kos, J. and T. Lah: Cysteine proteinases and their endogenous inhibitors: target proteins for prognosis, diagnosis, and therapy in cancer (Review). Oncol Rep 5, 1349-1361(1998) (Pubitemid 28474074)
23. Kopitar-Jerala, N.: The role of cystatins in cells of the immune system. FEBS Letters 580, 6295-6301(2006) (Pubitemid 44750929)
24. Rawlings, N., F. Morton and A. Barrett: MEROPS: the peptidase database. Nucleic Acids Res. 34, D270-D272 (2006)
25. Rawlings, N., D. Tolle and A. Barrett: Evolutionary families of peptidase inhibitors. Biochem J. 378, 705-716(2004) (Pubitemid 38406845)
26. Bode, W., R. Engh, D. Musil, U. Thiele, R. Huber, A. Karshikov, J. Brzin, J. Kos and V. Turk: The 2.0 A X-ray crystal structure of chicken egg white cystatin and its possible mode of interaction with cysteine proteinases. Eur. Mol. Biol. Org. J. 7, 2593-2599(1988)
27. Turk, V. and W. Bode: The cystatins: protein inhibitors of cysteine proteinases. FEBS Letters 285, 213-219(1991)
28. Jones, C., A. Mackay, A. Grigoriadis, A. Cossu, J. Reis-Filho, L. Fulford, T. Dexter, S. Davies, K. Bulmer, E. Ford, S. Parry, M. Budroni, G. Palmieri, A. Neville, M. O'Hare and S. Lakhani: Expression profiling of purified normal human luninal and myoepithelial breast cells: indentifcation of novel prognostic markers for breast cancer. Cancer Res. 64, 3037-3045(2004) (Pubitemid 38581402)
29. Kuopio, T., A. Kankaanranta, P. Jalava, P. Kronqvist, T. Kotkansalo, E. Weber and Y. Collan: Cysteine proteinase inhibitor cystatin A in breast cancer. Cancer Res. 58, 432-436(1998) (Pubitemid 28087402)
30. Sinha, A., B. Quast, M. Wilson, E. Fernandes, P. Reddy, S. Ewing and D. Gleason: Prediction of pelvic lymph node metastasis by the ratio of cathepsin B to stefin A in patients with prostate carcinoma. Cancer 94, 3141-3149(2002) (Pubitemid 34670497)
31. Lah, T., M. Kokalj-Kunovar, B. Strukelj, J. Pungercar, D. Barlic-Maganja, M. Drobnic-Kosorok, L. Kastelic, J. Babnik, R. Golouh and V. Turk: Stefins and lysosomal cathepsins B, L, and D in human breast carcinoma. Int. J. Cancer 50, 36-44(1992)
32. Elzagheid, A., T. Kuopio, S. Pyrhonen and Y. Collan: Lymph node status as a guide to selection of available prognostic markers in breast cancer: the clinical practice of the future? Diagnostic Path. 1, 41(2006)
33. Strojan, P., M. Budihna, L. Smid, B. Svetic, I. Vrhovec, J. Kos and J. Skrk: Prognostic significance of cysteine proteinases cathepsins B and L and their endogenous inhibitors stefins A and B in patients with squamous cell carcinoma of the head and neck. Clin. Cancer Res. 6, 1052-1062(2000) (Pubitemid 30159367)
34. Strojnik, T., I. Zajc, A. Bervar, B. Zidanik, R. Golouh, J. Kos, V. Dolenc and T. Lah: Cathepsin B and its inhibitor stefin A in brain tumors. Eur J. Physiol. 439(Supppl), R122-R123(2000)
35. Erdel, M., E. Spiess, G. Trefz, H. Boxberger and W. Ebert: Cell interactions and motility in human lung tumor cell lines HS-24 and SB-3 under the influence of extracellular matrix components and proteinase inhibitors. Anticancer Res. 12, 349-359(1992)
36. Boike, G., T. Lah, B. Sloane, J. Rozhin, K. Honn, R. Guirquis, M. Stracke, L. Liotta and E. Schiffmann: A possible role for cysteine proteinase and its inhibitors in motility of malignant melanoma and other tumour cells. Melanoma Res. 1, 333-340(1992)
37. Ohgaki, K., A. Iida, F. Kasumi, G. Sakamoto, M. Akimoto, Y. Nakamura and M. Emi: Mapping of a new target region of allelic loss to a 6-cM interval at 21q21 in primary breast cancers. Genes Chromosomes Cancer 23, 244-7(1998) (Pubitemid 28465641)
38. Widschwendter, M. and P. A. Jones: DNA methylation and breast carcinogenesis. Oncogene 21, 5462-82(2002) (Pubitemid 34983482)
39. Sato, N., N. Fukushima, A. Maitra, H. Matsubayashi, C. J. Yeo, J. L. Cameron, R. H. Hruban and M. Goggins: Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res 63, 3735-42(2003) (Pubitemid 36793060)
40. Suzuki, H., E. Gabrielson, W. Chen, R. Anbazhagan, M. van Engeland, M. P. Weijenberg, J. G. Herman and S. B. Baylin: A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet 31, 141-9(2002)
41. Liang, G., F. A. Gonzales, P. A. Jones, T. F. Orntoft and T. Thykjaer: Analysis of gene induction in human fibroblasts and bladder cancer cells exposed to the methylation inhibitor 5-aza-2'-deoxycytidine. Cancer Res 62, 961-6(2002) (Pubitemid 34160269)
42. Graff, J. R., E. Gabrielson, H. Fujii, S. B. Baylin and J. G. Herman: Methylation patterns of the E-cadherin 5' CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression. J Biol Chem 275, 2727-32(2000) (Pubitemid 30082043)
43. Arapshian A., Y. S. Kuppumbatti and R. Mira-y-Lopez: Methylation of conserved CpG sites neighboring the beta retinoic acid response element may mediate retinoic acid receptor beta gene silencing in MCF-7 breast cancer cells. Oncogene 19, 4066-70(2000)
44. Deng G., G. A. Song, E. Pong, M. Sleisenger and Y. S. Kim: Promoter methylation inhibits APC gene expression by causing changes in chromatin conformation and interfering with the binding of transcription factor CCAAT-binding factor. Cancer Res 64, 2692-8(2004) (Pubitemid 38500603)
45. Sathyanarayana, U. G., R. Maruyama, A. Padar, M. Suzuki, J. Bondaruk, A. Sagalowsky, J. D. Minna, E. P. Frenkel, H. B. Grossman, B. Czerniak and A. F. Gazdar: Molecular detection of noninvasive and invasive bladder tumor tissues and exfoliated cells by aberrant promoter methylation of laminin-5 encoding genes. Cancer Res 64, 1425-30(2004) (Pubitemid 38235612)
46. Sathyanarayana, U. G., A. Padar, C. X. Huang, M. Suzuki, H. Shigematsu, B. N. Bekele and A. F. Gazdar: Aberrant promoter methylation and silencing of laminin-5-encoding genes in breast carcinoma. Clin Cancer Res 9, 6389-94(2003) (Pubitemid 38031824)
47. Sathyanarayana, U. G., A. Padar, M. Suzuki, R. Maruyama, H. Shigematsu, J. T. Hsieh, E. P. Frenkel and A. F. Gazdar: Aberrant promoter methylation of laminin-5-encoding genes in prostate cancers and its relationship to clinicopathological features. Clin Cancer Res 9, 6395-400(2003) (Pubitemid 38031825)
48. Sathyanarayana, U. G., S. Toyooka, A. Padar, T. Takahashi, E. Brambilla, J. D. Minna and A. F. Gazdar: Epigenetic inactivation of laminin-5-encoding genes in lung cancers. Clin Cancer Res 9, 2665-72(2003) (Pubitemid 36842111)
49. Velculescu V., S. Madden, L. Zhang, A. Lash, J. Yu, C. Rago, A. Lal, C. Wang, G. Beaudry, K. Ciriello, B. Cook, M. Dufault, A. Ferguson, Y. Gao, T. He, H. Hermeking, S. Heraldo, P. Hwang, M. Lopez, H. Luderer, B. Mathews, J. Petroziello, K. Polyak, L. Zawel, K. Kinzler and e. al.: Analysis of human transcriptomes. Nat Genet. 23, 387-388(1999)
50. Lehesjoki, A. E.: Molecular background of progressive myoclonus epilepsy. Embo J 22, 3473-8(2003)
51. O'Brien, C.: Gene perplexes epilepsy researchers. Science 271, 1672(1996) (Pubitemid 26102814)
52. Werle B., U. Schanzenbacher, T. Lah, E. Ebert, B. Julke, W. Ebert, W. Fiehn, K. Kayser, E. Spiess, M. Abrahamson and J. Kos: Cystatins in non-small cell lung cancer: tissue levels, localization and relation to prognosis. Oncol Rep 16, 647-655(2006)
53. Zajc I., N. Sever, A. Bervar and T. Lah: Expression of cysteine peptidase cathepsin L and its inhibitors stefins A and B in relation to tumorigenicity of breast cancer cell lines. Cancer Letters 187, 185-190(2002) (Pubitemid 35279348)
54. Lah T., J. Kos, A. Blejec, S. Frkovic-Grazio, R. Golouh, I. Vrhovec and V. Turk: The expression of lysosomal proteinases and their inhibitors in breast cancer: possible realtionship to prognosis of the disease. Pathology Oncology Res. 3, 221-233(1997)
55. Levicar N., J. Kos, A. Blejec, R. Golouh, I. Vrhovec, S. Frkovic-Grazio and T. Lah: Comparison of cysteine proteinases cathepsin B, cathepsin L and serine proteinase urokinase (u-PA) and their endogenous inhibitors with clinico-pathological data of breast carcinoma patients. Cancer Detect. Prev. 26, 42-49(2002)
56. Momparler, R. L.: Cancer epigenetics. Oncogene 22, 6479-83(2003) (Pubitemid 37372327)
57. Prendergast, G. C. and E. B. Ziff: Methylation-sensitive sequence-specific DNA binding by the c-Myc basic region. Science 251, 186-9(1991) (Pubitemid 21916865)
58. Meehan, R. R., J. D. Lewis, S. McKay, E. L. Kleiner and A. P. Bird: Identification of a mammalian protein that binds specifically to DNA containing methylated CpGs. Cell 58, 499-507(1989) (Pubitemid 19203534)
59. Lux W., H. G. Klobeck, P. B. Daniel, M. Costa, R. L. Medcalf and W. D. Schleuning: In vivo and in vitro analysis of the human tissue-type plasminogen activator gene promoter in neuroblastomal cell lines: evidence for a functional upstream kappaB element. J Thromb Haemost 3, 1009-17(2005) (Pubitemid 41632833)
60. Shridhar R., J. Zhang, J. Song, B. A. Booth, C. G. Kevil, G. Sotiropoulou, B. F. Sloane and D. Keppler: Cystatin M suppresses the malignant phenotype of human MDA-MB-435S cells. Oncogene 23, 2206-15(2004) (Pubitemid 38482535)
61. Keppler D., P. Waridel, M. Abrahamson, D. Bachmann, J. Berdoz and B. Sordat: Latency of cathepsin B secreted by human colon carcinoma cells is not linked to secretion of cystatin C and is relieved by neutrophil elastase. Biochim Biophys Acta 1226, 117-25(1994) (Pubitemid 24182454)
62. Rawlings, N. D. and A. J. Barrett: Evolution of proteins of the cystatin superfamily. J Mol Evol 30, 60-71(1990) (Pubitemid 20050148)
63. Turk B., D. Turk and G. S. Salvesen: Regulating cysteine protease activity: essential role of protease inhibitors as guardians and regulators. Curr Pharm Des 8, 1623-37(2002) (Pubitemid 34752830)
64. Harmoinen A., E. Ylinen, M. Ala-Houhala, M. Janas, M. Kaila and T. Kouri: Reference intervals for cystatin C in pre-and full-term infants and children. Pediatr Nephrol 15, 105-8(2000)
65. Koenig W., D. Twardella, H. Brenner and D. Rothenbacher: Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate. Clin Chem 51, 321-7(2005) (Pubitemid 40175801)
66. Lignelid, H. and B. Jacobsson: Cystatin C in the human pancreas and gut: an immunohistochemical study of normal and neoplastic tissues. Virchows Arch A Pathol Anat Histopathol 421, 491-5(1992) (Pubitemid 23008254)
67. Lignelid H., V. P. Collins and B. Jacobsson: Cystatin C and transthyretin expression in normal and neoplastic tissues of the human brain and pituitary. Acta Neuropathol (Berl) 93, 494-500(1997) (Pubitemid 27186990)
68. Jacobsson B., H. Lignelid and U. S. Bergerheim: Transthyretin and cystatin C are catabolized in proximal tubular epithelial cells and the proteins are not useful as markers for renal cell carcinomas. Histopathology 26, 559-64(1995)
69. Hirai K., M. Yokoyama, G. Asano and S. Tanaka: Expression of cathepsin B and cystatin C in human colorectal cancer. Hum Pathol 30, 680-6(1999) (Pubitemid 29266728)
70. Vigneswaran, N., J. Wu, S. Muller, W. Zacharias, S. Narendran and L. Middleton: Expression analysis of cystatin C and M in laser-capture microdissectioned human breast cancer cells - a preliminary study. Pathol Res Pract 200, 753-62(2005) (Pubitemid 40220956)
71. Kos J., M. Krasovec, N. Cimerman, H. J. Nielsen, I. J. Christensen and N. Brunner: Cysteine proteinase inhibitors stefin A, stefin B, and cystatin C in sera from patients with colorectal cancer: relation to prognosis. Clin Cancer Res 6, 505-11(2000) (Pubitemid 30111471)
72. Kos J., B. Stabuc, A. Schweiger, M. Krasovec, N. Cimerman, N. Kopitar-Jerala and I. Vrhovec: Cathepsins B, H, and L and their inhibitors stefin A and cystatin C in sera of melanoma patients. Clin Cancer Res 3, 1815-22(1997) (Pubitemid 27444722)
73. Zore I., M. Krasovec, N. Cimerman, R. Kuhelj, B. Werle, H. J. Nielsen, N. Brunner and J. Kos: Cathepsin B/cystatin C complex levels in sera from patients with lung and colorectal cancer. Biol Chem 382, 805-10(2001) (Pubitemid 32631718)
74. Domej W., G. P. Tilz, Z. Foldes-Papp, U. Demel, T. Rabold and H. Holzer: Cystatin C of pleural effusion as a novel diagnostic aid in pleural diseases of different aetiologies. Clin Sci (Lond) 102, 373-80(2002) (Pubitemid 34214401)
75. Werle B., K. Sauckel, C. M. Nathanson, M. Bjarnadottir, E. Spiess, W. Ebert and M. Abrahamson: Cystatins C, E/M and F in human pleural fluids of patients with neoplastic and inflammatory lung disorders. Biol Chem 384, 281-7(2003) (Pubitemid 36348328)
76. Kos J., B. Werle, T. Lah and N. Brunner: Cysteine proteinases and their inhibitors in extracellular fluids: markers for diagnosis and prognosis in cancer. Int J Biol Markers 15, 84-9(2000) (Pubitemid 30195490)
77. Corticchiato O., J. F. Cajot, M. Abrahamson, S. J. Chan, D. Keppler and B. Sordat: Cystatin C and cathepsin B in human colon carcinoma: expression by cell lines and matrix degradation. Int J Cancer 52, 645-52(1992)
78. Coulibaly S., H. Schwihla, M. Abrahamson, A. Albini, C. Cerni, J. L. Clark, K. M. Ng, N. Katunuma, O. Schlappack, J. Glossl and L. Mach: Modulation of invasive properties of murine squamous carcinoma cells by heterologous expression of cathepsin B and cystatin C. Int J Cancer 83, 526-31(1999) (Pubitemid 29489869)
79. Konduri, S. D., N. Yanamandra, K. Siddique, A. Joseph, D. H. Dinh, W. C. Olivero, M. Gujrati, G. Kouraklis, A. Swaroop, A. P. Kyritsis and J. S. Rao: Modulation of cystatin C expression impairs the invasive and tumorigenic potential of human glioblastoma cells. Oncogene 21, 8705-12(2002) (Pubitemid 36132391)
80. Sokol, J. P. and W. P. Schiemann: Cystatin C antagonizes transforming growth factor beta signaling in normal and cancer cells. Mol Cancer Res 2, 183-95(2004) (Pubitemid 39030308)
81. Solem M., C. Rawson, K. Lindburg and D. Barnes: Transforming growth factor beta regulates cystatin C in serum-free mouse embryo (SFME) cells. Biochem Biophys Res Commun 172, 945-51(1990) (Pubitemid 20384515)
82. Sotiropoulou G., A. Anisowicz and R. Sager: Identification, cloning, and characterization of cystatin M, a novel cysteine proteinase inhibitor, down-regulated in breast cancer. J Biol Chem 272, 903-10(1997) (Pubitemid 27034580)
83. Ni J., M. Abrahamson, M. Zhang, M. A. Fernandez, A. Grubb, J. Su, G. L. Yu, Y. Li, D. Parmelee, L. Xing, T. A. Coleman, S. Gentz, R. Thotakura, N. Nguyen, M. Hesselberg and R. Gentz: Cystatin E is a novel human cysteine proteinase inhibitor with structural resemblance to family 2 cystatins. J Biol Chem 272, 10853-8(1997) (Pubitemid 27181102)
84. Vigneswaran N., J. Wu, N. Nagaraj, R. James, P. Zeeuwen and W. Zacharias: Silencing of cystatin M in metastatic oral cancer cell line MDA-686Ln by siRNA increase cysteine proteinases and legumain activities, cell proliferation and in vitro invasion. Life Sciences 78, 898-907(2006) (Pubitemid 43082316)
85. Lah, T. and J. Kos: Cysteine proteinases in cancer progression and their clinical relevance for prognosis. Biol Chem 379, 125-130(1998) (Pubitemid 28075971)
86. Frosch B., I. Berquin, M. Emmert-Buck, K. Moin and B. Slone: Molecular regulation, membrane association and secretion of tumor cathepsin B. Apmis 107, 28-37(1999) (Pubitemid 29133520)
87. Zeeuwen, P. L.: Epidermal differentiation: the role of proteases and their inhibitors. Eur J Cell Biol 83, 761-73(2004) (Pubitemid 40123840)
88. Zeeuwen, P. L., I. M. van Vlijmen-Willems, H. Egami and J. Schalkwijk: Cystatin M/E expression in inflammatory and neoplastic skin disorders. Br J Dermatol 147, 87-94(2002) (Pubitemid 34779442)
89. Zhang J., R. Shridhar, Q. Dai, J. Song, S. C. Barlow, L. Yin, B. F. Sloane, F. R. Miller, C. Meschonat, B. D. Li, F. Abreo and D. Keppler: Cystatin m: a novel candidate tumor suppressor gene for breast cancer. Cancer Res 64, 6957-64(2004) (Pubitemid 39331005)
90. Song J., C. Jie, P. Polk, R. Shridhar, T. Clair, J. Zhang, L. Yin and D. Keppler: The candidate tumor suppressor CST6 alters the gene expression profile of human breast carcinoma cells: down-regulation of the potent mitogenic, motogenic, and angiogenic factor autotaxin. Biochem and Biophy Res Comm 340, 175-182(2006) (Pubitemid 41827662)
91. Srivatsan, E. S., R. Chakrabarti, K. Zainabadi, S. D. Pack, P. Benyamini, M. S. Mendonca, P. K. Yang, K. Kang, D. Motamedi, M. P. Sawicki, Z. Zhuang, R. A. Jesudasan, U. Bengtsson, C. Sun, B. A. Roe, E. J. Stanbridge, S. P. Wilczynski and J. L. Redpath: Localization of deletion to a 300 Kb interval of chromosome 11q13 in cervical cancer. Oncogene 21, 5631-42(2002) (Pubitemid 34983553)
92. Cromer A., A. Carles, R. Millon, G. Ganguli, F. Chalmel, F. Lemaire, J. Young, D. Dembele, C. Thibault, D. Muller, O. Poch, J. Abecassis and B. Wasylyk: Identification of genes associated with tumorigenesis and metastatic potential of hypopharyngeal cancer by microarray analysis. Oncogene 23, 2484-98(2004) (Pubitemid 38520746)